Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last SFr.90.45 CHF
Change Today -0.25 / -0.28%
Volume 8.5K
YPSN On Other Exchanges
YPSN is not on other exchanges.
As of 6:15 AM 04/28/15 All times are local (Market data is delayed by at least 15 minutes).

ypsomed holding ag-reg (YPSN) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/30/14 - SFr.93.67
52 Week Low
01/22/15 - SFr.76.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for YPSOMED HOLDING AG-REG (YPSN)

Related News

No related news articles were found.

ypsomed holding ag-reg (YPSN) Related Businessweek News

No Related Businessweek News Found

ypsomed holding ag-reg (YPSN) Details

Ypsomed Holding AG develops, manufactures, and sells injection pens for pharmaceutical and biotech companies worldwide. The company operates in two segments, Delivery Devices and Diabetes Direct Business. The Delivery Devices segment products include pen systems, pen needles, infusion sets, and other injection moldings products. The Diabetes Direct Business sells and trades devices for the self-monitoring of blood glucose levels, as well as infusion pumps, accessories, and other day-to-day items for diabetics. It offers insulin pumps, injection systems, and pen needles for the treatment of diabetes, growth disorders, infertility, and other therapeutic areas; and pen needles under the mylife Diabetescare brand for the treatment of diabetes. Ypsomed Holding AG markets its products through biotech and pharmaceutical partners, as well as through its own distribution network and independent distributors. The company was founded in 1984 and is headquartered in Burgdorf, Switzerland.

989 Employees
Last Reported Date: 11/7/14
Founded in 1984

ypsomed holding ag-reg (YPSN) Top Compensated Officers

Senior Vice President of Legal & Intellectual...
Total Annual Compensation: SFr.387.0K
Compensation as of Fiscal Year 2014.

ypsomed holding ag-reg (YPSN) Key Developments

Ypsomed Group Announces Executive Changes, Effective October 2015

Ypsomed Group has appointed Frank Mengis as COO, effective October 2015. Mr. Mengis will succeed Dr. Benjamin Reinmann, who is leaving the Burgdorf-based medical technology group at his own request. Mr. Mengis, who has German-Swiss dual citizenship, has a wealth of experience in production-related areas gained in various positions in the medical technology sector during his career to date. He worked in the Straumann Group for eleven years, where he was responsible for areas including development, quality management and global manufacturing. In his most recent position at Nobel Biocare, he was a member of the Executive Committee as Head of Global Operations. In his position as COO for the Ypsomed Group, will be in charge of production, quality management and logistics.

Ypsomed Group Announces Earnings Results for the First Half Ended September 30, 2014; Provides Earnings Guidance for the Fiscal Year 2015

Ypsomed Group announced earnings results for the first half ended September 30, 2014. For the period, the company reported operating profit of CHF 12,923,000 against CHF 4,644,000 a year ago. Net profit was CHF 9,098,000 against CHF 4,600,000 a year ago. Earnings per share were CHF 0.72 against CHF 0.36 a year ago. Consolidated sales were CHF 148,522,000 against CHF 131,473,000 a year ago. Ypsomed is raising its forecast for the end of the 2014/15 financial year and is anticipating sales growth of over 10% and EBIT of some CHF 27 million.

Ypsomed Holding Gets Order from Astra-Zeneca for Insulin Pens

Ypsomed Holding AG announced that it will supply Astra-Zeneca with its injection system LyoTwist for administering its diabetes drug Bydureon. The company did not disclose financial details, but a spokesperson announced that Swiss agency AWP the investment for the development of an insulin pen usually amounts to around CHF 10 million (USD 10.6 million/EUR 8.2 million). The cooperation will shorten AstraZeneca's time to the market, while it also proves that Ypsomed`s decision to invest in injection systems was right.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
YPSN:SW SFr.90.45 CHF -0.25

YPSN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Antares Pharma Inc $2.63 USD -0.09
Bioject Medical Technologies Inc $0.10 USD -0.005
Terumo Corp ¥3,190 JPY +35.00
Unilife Corp $3.49 USD -0.07
West Pharmaceutical Services Inc $55.93 USD -1.45
View Industry Companies

Industry Analysis


Industry Average

Valuation YPSN Industry Range
Price/Earnings 63.2x
Price/Sales 3.9x
Price/Book 4.9x
Price/Cash Flow 63.4x
TEV/Sales 3.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact YPSOMED HOLDING AG-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at